Edwards Finds Transcatheter Valve Adoption In U.S. Slower Than Expected

Edwards Lifesciences is lowering its revenue expectations for 2013 based on adoption rates so far of its transcatheter aortic valve implant technology.

More from Archive

More from Medtech Insight